Kidney Week

Abstract: SA-PO0455

Prescribing Patterns for Renoprotective Medications in Diabetic Kidney Disease

Session Information

• CKM: Clinical - Screening, Population Management, Care Disparities, and Patient-Centered Outcomes
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Cardiovascular-Kidney-Metabolic Health

• 602 Cardiovascular-Kidney-Metabolic Health: Clinical

Authors

• Kowalczyk, Nicholas Stanley, The University of Chicago, Chicago, Illinois, United States

Nicholas Stanley Kowalczyk, MD

• McGill, Rita L., The University of Chicago, Chicago, Illinois, United States

Rita L. McGill, MD, MS, FASN

• Calip, Gregory S., University of Southern California, Los Angeles, California, United States

Gregory S. Calip, PharmD, PhD, MPH

• Laiteerapong, Neda, The University of Chicago, Chicago, Illinois, United States

Neda Laiteerapong, MD, MS

• Saunders, Milda R., The University of Chicago, Chicago, Illinois, United States

Milda R. Saunders, MD, MPH

Background

KDIGO guidelines advocate treatment with renoprotective medications (Rx) including RAAS, SGLT2i, ns-MRA, and GLP-1 agonists in diabetic kidney disease (DKD).

Methods

Descriptive analysis of Rx uptake with calendar-year trends among adults with type 2 diabetes, stratified by diagnosis of CHF, seen by primary care, nephrology, or endocrinology at an urban tertiary center serving a predominantly Black population. Patients with ESKD, type 1 diabetes, or allergies to Rx were excluded. Multivariable logistic regression model used to identify patient and clinician-level correlates of Rx use in 2024, the latest year of study.

Results

Rates of RAAS, SGLT2i, and GLP-1 increased over time, most notably for individuals with CHF. ns-MRA use was minimal (<1%). Women were less likely to be prescribed RAAS or SGLT2i but more likely to be prescribed GLP-1 compared to men. Black patients were more likely to be prescribed all three classes compared to Whites. Patients aged 18-44 years were less likely to be prescribed RAAS and SGLT2i but more likely to be prescribed GLP-1. Low eGFR (<30) was associated with lower odds of RAAS or SGLT2i prescriptions but not for GLP-1. Those seen by nephrology had a greater odds of RAAS prescription, while those seen by endocrine had greater odds of GLP-1 agonists prescription.

Conclusion

Despite improvements over time, there are opportunities for further uptake of agents in DKD particularly among young patients, women, and patients with low eGFR.

Funding

• NIDDK Support